ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: The current standard of care for PTCL is CHOP therapy including the CHOP-L regimen [10]; however, it has been reported that PTCL shows a generally poor prognosis, with 5-year OS rates of only 32 % in PTCL-NOS and AITL, except for in anaplastic lymphoma kinase (ALK)-positive ALCL, which is associated with a 5-year OS rate of 70 % [6].